Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RCEL 
Avita Medical Ltd (RCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 28.43% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 215.34M USD | Price to earnings Ratio - | 1Y Target Price 17.3 |
Price to earnings Ratio - | 1Y Target Price 17.3 | ||
Volume (30-day avg) 196338 | Beta 1.57 | 52 Weeks Range 7.51 - 15.66 | Updated Date 04/1/2025 |
52 Weeks Range 7.51 - 15.66 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -96.26% | Operating Margin (TTM) -54.1% |
Management Effectiveness
Return on Assets (TTM) -36.97% | Return on Equity (TTM) -230.96% |
Valuation
Trailing PE - | Forward PE 136.99 | Enterprise Value 224650391 | Price to Sales(TTM) 3.35 |
Enterprise Value 224650391 | Price to Sales(TTM) 3.35 | ||
Enterprise Value to Revenue 3.5 | Enterprise Value to EBITDA -6.17 | Shares Outstanding 26357500 | Shares Floating 25847260 |
Shares Outstanding 26357500 | Shares Floating 25847260 | ||
Percent Insiders 0.82 | Percent Institutions 24.74 |
Analyst Ratings
Rating 4.33 | Target Price 17.16 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avita Medical Ltd
Company Overview
History and Background
Avita Medical Ltd, formerly known as Clinical Cell Culture, was founded in 1993 in Australia. It focuses on regenerative medicine, pioneering innovative solutions for skin restoration and wound healing. It gained FDA approval for RECELL Autologous Cell Harvesting Device in 2018, marking a significant milestone.
Core Business Areas
- Wound Care: Avita Medical's primary focus is on developing and commercializing innovative products for wound care, including burn treatment and other skin defects.
- Regenerative Medicine: The company is involved in regenerative medicine, aiming to develop therapies that promote tissue regeneration and healing.
Leadership and Structure
Avita Medical Ltd's leadership team consists of experienced professionals in the medical device and biotechnology industries. The organizational structure is designed to support research and development, commercialization, and global expansion.
Top Products and Market Share
Key Offerings
- RECELL System: RECELL Autologous Cell Harvesting Device is Avita Medical's flagship product. It allows healthcare professionals to create Spray-On Skinu2122 Cells using a small sample of a patient's own skin, promoting faster healing of burns and other wounds. Competitors include conventional skin grafting techniques and other advanced wound care products. Market share is growing as it gains broader acceptance, but precise figures are hard to ascertain due to the fragmentation of the wound care market. Key competition includes Smith & Nephew (SNN), Integra LifeSciences (IART), and Molnlycke.
Market Dynamics
Industry Overview
The wound care market is driven by an aging population, increasing incidence of diabetes, and rising number of burn injuries. Advanced wound care technologies are gaining traction over traditional methods.
Positioning
Avita Medical is positioned as a leader in regenerative medicine for wound care, offering innovative solutions that reduce the need for extensive skin grafting. Its competitive advantage lies in its proprietary RECELL technology.
Total Addressable Market (TAM)
The global advanced wound care market is expected to reach approximately $22 billion by 2029. Avita Medical is well-positioned to capture a significant share of this market with its innovative products.
Upturn SWOT Analysis
Strengths
- Proprietary RECELL technology
- FDA approval for RECELL System
- Growing clinical evidence supporting the efficacy of RECELL
- Strong focus on regenerative medicine
Weaknesses
- Limited market penetration compared to established competitors
- Reliance on a single core product (RECELL)
- Relatively small company size compared to major players in the wound care market
Opportunities
- Expanding the indications for RECELL to include other wound types
- Gaining market share through strategic partnerships and collaborations
- Expanding into new geographic markets
- Developing new regenerative medicine products
Threats
- Competition from established players in the wound care market
- Potential for new competing technologies to emerge
- Regulatory hurdles and reimbursement challenges
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- SNN
- IART
- MOLN
Competitive Landscape
Avita Medical's RECELL offers a distinct advantage in reducing the need for extensive skin grafting. However, established players like Smith & Nephew have broader product portfolios and larger sales forces. Avita needs to scale operations to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Avita Medical has experienced significant revenue growth since the FDA approval of RECELL. This growth has been fueled by increasing adoption of the product in burn centers and other wound care settings.
Future Projections: Analyst estimates suggest continued revenue growth for Avita Medical as it expands its market reach and secures additional approvals. Exact figures depend on third-party analyst reports.
Recent Initiatives: Recent initiatives include expanding the sales force, conducting clinical trials for new indications, and forming partnerships with healthcare providers.
Summary
Avita Medical is a growing company with a promising regenerative medicine technology for wound care. Its RECELL system offers clinical advantages, but it faces stiff competition from larger, more established players. Continued growth depends on expanding market penetration and securing favorable reimbursement policies. Recent initiatives towards new clinical trials for other wounds are good indicators.
Similar Companies
- SNN
- IART
- MOLN
- BSX
- ABMD
Sources and Disclaimers
Data Sources:
- Company filings
- Press releases
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avita Medical Ltd
Exchange NASDAQ | Headquaters Valencia, CA, United States | ||
IPO Launch date 2019-10-01 | CEO, President & Executive Director Mr. James M. Corbett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 260 | Website https://avitamedical.com |
Full time employees 260 | Website https://avitamedical.com | ||
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.